🟢 Kura Oncology is trading 11.29% up in pre-market after CEO discloses another 100,000-share purchase

Kura Oncology is trading 11.29% up in pre-market at $13.80 after President and CEO Troy Wilson disclosed another purchase of 100,000 shares on August 24, 2026.

• The after-session filing followed his earlier August purchase, reinforcing insider-buying sentiment.
• The transaction was reportedly worth approximately $1.24 million at $12.39 per share.
• Shares closed at $12.40 on August 24, up 4.29%; broader markets are firmer pre-market, but the CEO purchase is the clearest catalyst.